{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017868","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.286684+00:00","generated_at":"2026-06-15T21:48:16.128062+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sight Sciences Q1 revenue up 26% to $18.8M, net loss $17.1M; reaffirms FY2023 guidance","bullets":["Revenue $18.8M (+26% YoY); Surgical Glaucoma $17.3M (+25%), Dry Eye $1.5M (+47%).","Net loss $17.1M ($0.35/share) vs $23.3M ($0.49) prior year; operating expenses decreased 2% to $33.3M.","Gross margin improved to 84% from 80% due to prior year voluntary TearCare SmartHub replacement.","Reaffirmed FY2023 revenue guidance $89-94M (25-32% growth) and ~$30.5M quarterly adjusted opex.","Completed commercial launch of Ergo-Series OMNI Surgical System; cash $167.3M, debt $35.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017868","json":"https://secwatch.observer/filing/0000950170-23-017868.json","markdown":"https://secwatch.observer/filing/0000950170-23-017868.md","text":"https://secwatch.observer/filing/0000950170-23-017868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023017868/0000950170-23-017868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023017868/sght-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:48:16.128062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3dbecfca9196e872b1cda8ec9d7417c523a1c5a6","claim":"Sight Sciences, Inc. reported the first quarter ended March 31, 2023 results: revenue $18.8 million, net income $17.1 million, EPS ($0.35) per share. Guidance reaffirmed.","evidence_excerpt":"results for the first quarter ended March 31, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights • Generated first quarter revenue of $18.8 million, an increase of 26% compared to the prior year period • Achieved gross margin of 84% in the first quarter of 2023 versus 80% in the first quarter of 2022 • Completed the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1531177/000095017023017868/0000950170-23-017868-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$18.8 million"},{"label":"Net income","value":"$17.1 million"},{"label":"EPS","value":"($0.35) per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}